Present status of treatment in nasopharyngeal carcinoma?;Wo stehen wir bei der behandlung des nasopharynx-karzinoms?

Strahlentherapie und Onkologie

Volumn 179, Issue 5, 2003, Pages 283-291

  Beckmann, Gabriele ^a   Flentje, Michael ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Combined chemoradiotherapy; Nasopharyngeal cancer; Prognostic factors; Radiation treatment

Indexed keywords

BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; VINCRISTINE;

CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; DOSE RESPONSE; FRACTIONATION; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; NASOPHARYNX CARCINOMA; PROGNOSIS; RACE DIFFERENCE; RADIATION DOSE; REVIEW; TREATMENT PLANNING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRACHYTHERAPY; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS, PHASE II; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DOSE FRACTIONATION; HUMANS; LYMPHATIC METASTASIS; MULTICENTER STUDIES; NASOPHARYNGEAL NEOPLASMS; NASOPHARYNX; NEOADJUVANT THERAPY; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; RADIOTHERAPY; RADIOTHERAPY DOSAGE; RANDOMIZED CONTROLLED TRIALS; REMISSION INDUCTION; TIME FACTORS;

EID: 0037987919     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00066-003-1086-0     Document Type: Review

References (51)

1. Al-Sarraf M, LeBlanc M, Giri PG. Superiority of 5-year survival with chemoradiotherapy vs. radiotherapy in patients with locally advanced nasopharyngeal cancer. Intergroup 0099 phase III study: Final report. Proceedings ASCO 2001;20:227a.
2. Al-Sarraf M, LeBlanc M, Giri PG, Fu KK, Cooper J, Vuong T, Forastiere AA, Adams G, Sakr WA, Schuller DE, Ensley JF. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup Study 0099. J Clin Oncol 1998;16:1310-7.
3. Al-Sarraf M, Pajak TF, Cooper JS, Mohiuddin M, Herskovic A, Ager PJ. Chemo-radiotherapy in patients with locally advanced nasopharyngeal carcinoma: a Radiation Therapy Oncology Group study. J Clin Oncol 1990;8: 1342-51.
4. Altun M, Fandi, A Dupuis O, Cvitkovic E, Krajina Z, Eschwege F. Undifferentiated nasopharyngeal cancer (UCNT): Current diagnostic and therapeutic aspects. Int J Radiat Oncol Biol Phys 1995;32:859-77.
5. Bedwinek JM, Perez CA, Keys DJ. Analysis of failures after definitive irradiation for epidermoid carcinoma of the nasopharynx. Cancer 1980;45: 2725-9.
6. Bratengeier K. Applications of two-step intensity modulated arc therapy. Strahlenther Onkol 2001;177:394-403.
7. Chan AT, Teo PM, Leung TW, Johnson PJ. The role of chemotherapy in the management of nasopharyngeal carcinoma. Cancer 1998;82:1003-12.
8. Chan AT, Teo PM, Leung TW, Leung SF, Lee WY, Yeo W, Choi PH, Johnson PJ. A prospective randomized study of chemotherapy adjunctive to definitive radiotherapy in advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 1995;33:569-77.
9. Chan AT, Teo PM, Ngan RK, Leung TW, Lau WH, Zee B, Leung SF, Cheung FY, Yeo W, Yiu HH, Yu KH, Chiu KW, Chan DT, Mok T, Yuen KT, Mo F, Lai M, Kwan WH, Choi P, Johnson PJ. Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a phase III randomized trial. J Clin Oncol 2002;20:2038-44.
10. Cheng SH, Tsai SY, Yen KL, Jian JJ, Chu NM, Chan KY, Tan TD, Cheng JC, Hsieh CY, Huang AT. Concomitant radiotherapy and chemotherapy for early-stage nasopharyngeal carcinoma. J Clin Oncol 2000;18:2040-5.
11. Chi KH, Chang YC, Guo WY, Leung MJ, Shiau CY, Chen SY, Wang LW, Lai YL, Hsu MM, Lian SL, Chang CH, Liu TW, Chin YH, Yen SH, Perng CH, Chen KY. A phase III study of adjuvant chemotherapy in advanced nasopharyngeal carcinoma patients. Int J Radiat Oncol Biol Phys 2002;52:1238-44.
12. Chua DT, Sham JS, Au GKH, Choy D. Concomittant chemoirradiation for stage III-IV nasopharyngeal carcinoma in chinese patients: results of a matched cohort analysis. Int J Radiat Oncol Biol Phys 2002;53:334-43.
13. Chua DT, Sham JS, Choy D, Kwong DL, Au GK, Kwong PW, Yau CC, Cheng AC, Wan KY. Patterns of failure after induction chemotherapy and radiotherapy for locoregionally advanced nasopharyngeal carcinoma: the Queen Mary Hospital experience. Int J Radiat Oncol Biol Phys 2001;49:1219-28.
14. Chua DT, Sham JS, Choy D, Lorvidhaya V, Sumitsawan Y, Thongprasert S, Vootiprux V, Cheirsilpa A, Azhar T, Reksodiputro AH. Preliminary report of the Asian-Oceanian Clinical Oncology Association randomized trial comparing cisplatin and epirubicin followed by radiotherapy versus radiotherapy alone in the treatment of patients with locoregionally advanced nasopharyngeal carcinoma. Cancer 1998;83:2270-83.
15. Cooper JS. Concurrent Chemotherapy and radiation therapy for advanced stage carcinoma of the nasopharynx. Int J Radiat Oncol Biol Phys 2000; 48:1277-9.
16. Cooper JS, Lee H, Torrey M, Hochester H. Improved outcome secondary to concurrent chemoradiotherapy for advanced carcinoma of the nasopharynx: preliminary corroboration of the intergroup experience. Int J Radiat Oncol Biol Phys 2000;47:861-6.
17. Dimery IW, Legha SS, Peters LJ, Goepfert H, Oswald MJ. Adjuvant chemotherapy for advanced nasopharyngeal carcinoma. Cancer 1987;60:943-9.
18. El-Sayed S, NeLson N. Adjuvant and adjunctive chemotherapy in the management of sqamous cell carcinoma of the head and neck region: a meta-analysis or prospective and randomized trials. J Clin Oncol 1996;14:838-47.
19. Guedari E. Final results of the VUMCA I randomized trial comparing neoadjuvant chemotherapy (BEC) plus radiotherapy to radiotherapy alone in undifferentiated nasopharyngeal cancer. Proc Am Soc Clin Oncol 1998;17:385a.
20. Gruner A, Grabenbauer GG, Rodel C, Weidenbecher M, Martus P, Iro H, Sauer R. Nasopharyngeal carcinoma: only irradiation or simultaneous radiochemotherapy? Strahtenther Onkol 1999;175:591-6.
21. Heng DM, Wee, J, Fong KW, Lian LG, Sethi VK, Chua ET, Yang TL, Khoo Tan HS, Lee KS, Lee KM, Tan T, Chua EJ. Prognostic factors in 677 patients in Singapore with nondisseminated nasopharyngeal carcinoma. Cancer 1999; 86:1912-20.
22. Hoppe RT, Goffinet DR, Bagshaw MA. Carcinoma of the nasopharynx. Eighteen years' experience with megavoltage radiation therapy. Cancer 1976; 37:2605-12.
23. Hong S, Wu HG, Chie EK, Bang YJ, Heo DS, Kim KH, Sung MW, Park CI. Neoadjuvant chemotherapy and radiation therapy compared with radiation therapy alone in advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 1999;45:901-5.
24. Hunt MA, Zelefsky MJ, Wolden S, Chui CS, LoSasso T, Rosenzweig K, Chong L, Spirou SV, Fromme L, Lumely M, Amols HA, Ling CC, Leibel SA. Treatment planning and delivery of intensity-modulated radiation therapy for primary nasopharynx cancer. Int J Radiat Oncol Biol Phys 2001;49:623-32.
25. Jen YM, Hsu WL, Chen CY, Hwang JM, Chang LP, Lin YS, Su WF, Chen CM, Liu DW, Chao HL. Different risks of symptomatic brain necrosis in NPC patients treated with different altered fractionated radiotherapy techniques. Int J Radiat Oncol Biol Phys 2001;51:344-8.
26. Jian JJ, Cheng SH, Tsai SY, Yen KC, Chu NM, Chan KY, Tan TD, Cheng JC, Lin YC, Leu SY, Hsieh CI, Tsou MH, Lin CY, Huang AT. Improvement of local control of T3 and T4 nasopharyngeal carcinoma by hyperfractionated radiotherapy and concomitant chemotherapy. Int J Radiat Oncol Biol Phys 2002;53:344-52.
27. Lee AW, Foo W, Chappell R, Fowler JF, Sze WM, Poon YF, Law SC, Ng SH, O SK, Tung SY, Lau WH, Ho JH. Effect of time, dose, and fractionation on temporal lobe necrosis following radiotherapy for nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 1998;40:35-42.
28. Lee AW, Kwong DL, Leung SF, Tung SY, Sze WM, Sham JS, Teo PM, Leung TW, Wu PM, Chappell R, Peters LJ, Fowler JF. Factors affecting risk of symptomatic temporal lobe necrosis: significance of fractional dose and treatment time. Int J Radiat Oncol Biol Phys 2002;53:75-85.
29. Lee AW, Poon YF, Foo W, Law SC, Cheung FK, Chan DK, Tung SY, Thaw M, Ho JH. Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976-1985: overall survival and patterns of failure. Int J Radiat Oncol Biol Phys 1992;23:261-70.
30. Lee AW, Sze WM, Yau TK, Yeung RM, Chappell R, Fowler JF. Retrospective analysis on treating nasopharyngeal carcinoma with accelerated fractionation (6 fractions per week) in comparison with conventional fractionation (5 fractions per week): report on 3-year tumor control and normal tissue toxicity. Radiother Oncol 2001;58:121-30.
31. Lu TX, Mai WY, The BS, Hu YH, Ju HH, Chiu JK, Carpenter LS, Woo SY, Butler EB. Important prognostic factors in patients with skull base erosion from nasopharyngeal carcinoma after radiotherapy. Int J Radiat Oncol Biol Phys 2001;51:589-98.
32. Ma J, Mai HQ, Hong MH, Cui NJ, Lu TX, Lu LX, Mo HY, Min HQ. Is the 1997 AJCC staging system for nasopharyngeal carcinoma prognostically useful for Chinese patient populations? Int J Radiat Oncol Biol Phys 2001;50: 1181-9.
33. Ma J, Mai HQ, Hong MH, Min HQ, Mao ZD, Cui NJ, Lu TX, Mo HY. Results of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. J Clin Oncol. 2001;19:1350-7.
34. Marks JE, Bedwinek JM, Lee F, Purdy JA, Perez CA. Dose-response analysis for nasopharyngeal carcinoma: an historical perspective. Cancer 1982; 50:1042-50.
35. Mesic JB, Fletcher GH, Goepfert H. Megavoltage irradiation of epithelial tumors of the nasopharynx. Int J Radiat Oncol Biol Phys 1981;7:447-53.
36. Munter MW, Debus J, Hof H, Nill S, Haring P, Bortfeld T, Wannenmacher M. Inverse treatment planning and stereotactic intensity-modulated radiation therapy (IMRT) of the tumor and lymph node levels for nasopharyngeal carcinomas. Description of treatment technique, plan comparison, and case study. Strahlenther Onkol 2002;178:517-23.
37. [No authors listed] Preliminary results of a randomized trial comparing neoadjuvant chemotherapy (cisplatin, epirubicin, bleomycin) plus radiotherapy vs. radiotherapy alone in stage IV (> or = N2, MO) undifferentiated nasopharyngeal carcinoma: a positive effect on progression-free survival. International Nasopharynx Cancer Study Group. VUMCA I trial. Int J Radiat Oncol Biol Phys 1996;35:463-9.
38. Perez CA, Devineni VR, Marcial-Vega V, Marks JE, Simpson JR, Kucik N. Carcinoma of the nasopharynx: factors affecting prognosis. Int J Radiat Oncol Biol Phys 1992;23:271-80.
39. Pignon JP, Bourhis J, Domenge C, Designé L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updatet individual data. Lancet 2000;355:949-55.
40. Qin DX, Hu YH, Yan JH, Xu GZ, Cai WM, Wu XL, Cao DX, Gu XZ. Analysis of 1379 patients with nasopharyngeal carcinoma treated by radiation. Cancer 1988;61:1117-24.
41. Rischin D, Corry J, Smith J, Stewart J, Hughes P, Peters L. Excellent disease control and survival in patients with advanced nasopharyngeal cancer treated with chemoradiation. J Clin Oncol 2002;20:1845-52.
42. Rossi A, Molinari R, Boracchi P, Del Vecchio M, Marubini E, Nava M, Morandi L, Zucali R, Pilotti S, Grandi C, et al. Adjuvant chemotherapy with vincristine, cyclophosphamide, and doxorubicin after radiotherapy in local-regional nasopharyngeal cancer: results of a 4-year multicenter randomized study. J Clin Oncol 1988;6:1401-10.
43. Sanguineti G, Geara FB, Garden AS, Tucker SL, Ang KK, Morrison WH, Peters LJ. Carcinoma of the nasopharynx treated by radiotherapy alone: determinants of local and regional control. Int J Radiat Oncol Biol Phys 1997;37:985-96.
44. Sham JS, Choy D, Choi PH. Nasopharyngeal carcinoma: the significance of neck node involvement in relation to the pattern of distant failure. Br J Radiol 1990;63:108-13.
45. Tan EH, Chua ET, Wee J, Tan T, Fong KW, Ang PT, Lee KS, Lee KM, Khoo-Tan HS, Leong SS, Ong YK, Foo KF, Sethi VK, Chua EJ. Concurrrent chemoradiotherapy followed by adjuvant chemotherapy in asian patients with nasopharyngeal carcinoma: toxicities and preliminary results. Int J Radiat Oncol Biol Phys 1999;45:597-601.
46. Teo PM, Chan AT, Lee WY, Leung TW, Johnson PJ. Enhancement of local control in locally advanced node-positive nasopharyngeal carcinoma by adjunctive chemotherapy. Int J Radiat Oncol Biol Phys 1999;43:261-71.
47. Teo PM, Leung SF, Chan AT, Leung TW, Choi PH, Kwan WH, Lee WY, Chau RM, Yu PK, Johnson PJ. Final report of a randomized trial on altered-fractionated radiotherapy in nasopharyngeal carcinoma prematurely terminated by significant increase in neurologic complications. Int J Radiat Oncol Biol Phys 2000;48:1311-22.
48. Vikram B, Mishra UB, Strong EW, Manolatos S. Patterns of failure in carcinoma of the nasopharynx: I. Failure at the primary site. Int J Radiat Oncol Biol Phys 1985;11:1455-9.
49. Wijers OB, Levendag PC, Luyten GP, Bakker BA, Freling NJ, Klesman-Bradley J, Woudstra E. Radiation-induced bilateral optic neuropathy in cancer of the nasopharynx. Case failure analysis and a review of the literature. Strahlenther Onkol 1999;175:21-7.
50. Wolden SL, Pfister DG, Kraus DH, Rosenzweig KE, Chong LM, Zhang H, Shaha AR, Harrison LB, Shah JP, Zelefsky MJ. Improved local control and survival with concomitant boost radiation therapy and chemotherapy for nasopharyngeal carcinoma. Proc ASCO 2000;19:415a.
51. Xiao GL, Gao L, Xu GZ. Prognostic influence of parapharyngeal space involvement in nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2002;52:957-63.